Lining up support for a New Technology Add-on Payment in a rare-disease treatment
A biopharma company wanted to know the likelihood of receiving an NTAP after launching an inpatient treatment
A biopharma company wanted to know the likelihood of receiving an NTAP after launching an inpatient treatment
Download to see features of the proposed rule
A pharma company needed to evaluate the likelihood that drug compendia would positively rate an off-label dosage of an FDA-approved medication to support additional payer coverage.
A biopharma company needed an appropriate pricing model for a new tablet formulation of a successful existing infusion